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Abstract
Recent development of benzoxaborole-based chemistry gave rise to a collection of com-
pounds with great potential in targeting diverse infectious diseases, including human African
Trypanosomiasis (HAT), a devastating neglected tropical disease. However, further medici-
nal development is largely restricted by a lack of insight into mechanism of action (MoA) in
pathogenic kinetoplastids. We adopted a multidisciplinary approach, combining a high-
throughput forward genetic screen with functional group focused chemical biological, struc-
tural biology and biochemical analyses, to tackle the complex MoAs of benzoxaboroles in
Trypanosoma brucei. We describe an oxidative enzymatic pathway composed of host semi-
carbazide-sensitive amine oxidase and a trypanosomal aldehyde dehydrogenase
TbALDH3. Two sequential reactions through this pathway serve as the key underlying
mechanism for activating a series of 4-aminomethylphenoxy-benzoxaboroles as potent try-
panocides; the methylamine parental compounds as pro-drugs are transformed first into
intermediate aldehyde metabolites, and further into the carboxylate metabolites as effective
forms. Moreover, comparative biochemical and crystallographic analyses elucidated the
catalytic specificity of TbALDH3 towards the benzaldehyde benzoxaborole metabolites as
xenogeneic substrates. Overall, this work proposes a novel drug activation mechanism
dependent on both host and parasite metabolism of primary amine containing molecules,
which contributes a new perspective to our understanding of the benzoxaborole MoA, and
could be further exploited to improve the therapeutic index of antimicrobial compounds.
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Author summary
Human African Trypanomiasis (HAT) is among a list of Neglected Tropical Diseases
(NTDs) that impose devastating burdens on both public health and economy of some of
the most unprivileged societies across the world. To secure the long-term global control of
the disease, it is critical to understand the mechanisms underlying the interactions of
drugs and drug candidates with the causative agents as well as resistance potentially aris-
ing from use of the compounds. We demonstrated here a metabolic enzymatic cascade
dependent on a host-pathogen interaction that determines potency against T. brucei of a
series of benzoxaborole compounds. More importantly, this pathway represents a meta-
bolic interaction network between host and pathogen, illuminating an important perspec-
tive on understanding mechanism of action.
Introduction
Encouraged by significant advances in the disease control since the close of the 20th century,
the World Health Organization (WHO) targeted HAT for eradication by 2020 [1]. A pressing
obstacle to achieving this goal is the limited and obsolete range of treatments available that are
compromised by deleterious side-effects, poor oral bioavailability and an alarming increase in
drug resistance in the field [2–5].
Several new candidate drugs have advanced through the development pipeline, including
acoziborole (SCYX-7158/AN5568) [6], a lead compound currently in a phase 2/3 clinical trial,
and AN7973/SCYX-1608210 and AN7119/SCYX1330682 as back-ups [7, 8]. These com-
pounds represent a class of hemiboronic acids with distinctive chemical and pharmacological
features [9, 10]. The cyclic boronic ester in the molecules provides a good balance between the
Lewis acidity essential for forming interactions with biochemical targets and the physicochem-
ical properties important for good bioavailability. Molecular insights into the mechanism of
action (MoA) in pathogenic model organisms has greatly contributed to development and
strategies for assessing potential risk of resistance for this series of molecules. However, the
benzoxaborole core structure is highly adaptive to substitution of function groups, which not
only contributes to great chemical diversity but also gives rise to a broad MoA spectrum. The
latter is manifested in a variety of targets and efficacy factors proposed from study of benzoxa-
boroles in various diseases and conditions, including proteases, phophodiesterases, kinases,
anhydrolases, aminoacyl-tRNA synthetases, reductases and RNA splicing factors [11–20]. Fur-
thermore, how the uptake and metabolism of these compounds occur in the context of infec-
tions remains as a significant gap in our understanding of benxoxaboroles. An earlier study
examining the impact of resistance to acoziborole, together with identification of possible
interacting proteins was inconclusive with regard to MoA [21].
Here, we adopted an approach combining forward genetics, biochemistry and structural
biology and identified a metabolic pathway critical for achieving the trypanocidal activity of a
series of 4-aminomethylphenoxy benzoxaboroles. The pathway involves two oxidation reac-
tions occurring sequentially in the host and the parasite. This highlights the importance of
metabolic interaction between host and pathogen [22–25] in considering novel MoAs, and
contributes to our improved understanding of benzoxaborole MoA.
Aminomethyl benzoxaborole activation enzymatic pathway
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Results
Genetic components that sensitize trypanosomes to
4-aminomethylphenoxy-benzoxaborole
We screened a set of benzoxoaboroles with variable substituents against a genome-scale RNAi
library in T. brucei [26, 27] to uncover the genetic factors that sensitize trypanosomes to the
compounds. These compounds included AN3054 and AN3057 that share a 4-aminomethyl-
phenoxy substituent linked via the 6- or 5-position of the benzoxaborole core, and acoziborole
that contains a 6-carboxyamide substituent (Fig 1A). We identified a high confidence hit,
Tb927.6.3050, specifically with the 4-aminomethylphenoxy derivatives (AN3054 and
AN3057), in addition to a cohort of candidates determining the sensitivity of the parasites
towards a broad range of benzoxaboroles (unpublished data).
Fig 1. Tb927.6.3050 serves as a specific potency determinant for aminomethylphenoxy benzoxaboroles. (A) Tb927.6.3050 identification in RIT-seq from a
genome-scale screening for potency determinants of benzoxaboroles. The gene locus is indicated in red, with flanking genes in black, in the relevant
chromosomal context. Each peak represents an identification by sequencing and the relative height corresponds to the number of reads. A pair of short
sequences were introduced in the original library [26], flanking the individual RNAi targeting fragment in both directions, as a unique bar code to ensure
sequencing specificity. The corresponding identifications are indicated in color, red for the forward sequence and blue for the reverse, distinguished from all
other identification indicated in grey. The aminomethylphenoxy moieties in the respective compounds are indicated with the dotted rectangles. (B) The
changes in potency (EC50) of chemically diverse benzoxaboroles upon Tb927.6.3050 RNAi.
https://doi.org/10.1371/journal.ppat.1006850.g001
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We then examined the impact of Tb927.6.3050 RNAi on the sensitivity of trypanosomes to
individual compounds (Fig 1B). Upon knockdown, the trypanosomes were significantly
desensitized to either AN3054 or AN3057 as opposed to acoziborole. Moreover, there was a
further divergence in the impact of the knockdown between AN3054 and AN3057, with more
profound impact on the latter. This is also consistent with the results from the initial genetics
screens where the signal for Tb927.6.3050 was more pronounced in the screen with AN3057
than with AN3054 (Fig 1A). Taken together, these data suggest a specific structure-activity
relationship (SAR) between Tb927.6.3050 and 4-aminomethylphenoxy derivatives.
The SAR between Tb927.6.5030 and 4-aminomethylphenoxy substituents
To define this SAR, we first investigated the correlation between the potency of related but dis-
tinctive phenoxy compounds and Tb927.6.3050 RNAi. Included were three aminomethylphe-
noxy-substitution (-CH2NH2) isomers, i.e. AN3057, AN3054 and AN3056, and three
carboxyphenoxy-substitution (-CO2H) isomers, i.e. AN2861, AN3330 and AN3410, with each
aminomethylphenoxy isomer paired with the corresponding carboxyphenoxy isomer as
shown in Fig 2. The potencies of all three aminomethylphenoxy isomers were significantly
compromised by the knockdown, in contrast to the impact of the carboxyphenoxy equivalents.
Thus, the methylamine moiety shared by the aminomethylphenoxy derivatives is the key link
to the function of Tb927.6.3050 in defining the potencies of this series of benzoxaboroles in T.
brucei.
Noticeably, among three aminomethylphenoxy isomers, there was a further variation in the
impact of the knockdown on drug potency; the highest impact was observed with AN3057
(ΔEC50120), followed by AN3056 (ΔEC507), and the least with AN3054 (ΔEC504). This
phenomenon suggests a differential contribution by Tb927.6.3050 to the anti-trypanosomal
activities of aminomethylphenoxy bezoxaboroles with further chemical diversity. Additionally,
we found in comparing the aminomethylphenoxy-carboxylate pair compounds that the
methylamine containing compounds are more potent than the carboxylate counterparts, with
~8 fold difference between AN3057 and AN2861, ~3 fold between AN3054 and AN3330, and
~15 fold between AN3056 and AN3410.
Tb927.6.5030 encodes a putative fatty aldehyde dehydrogenase (FALDH)
Next, we took a comparative genomics approach to elaborate the function of Tb927.6.3050,
which was previously uncharacterised [28]. We constructed a phylogenetic tree for all mem-
bers of the ALDH superfamily currently known in humans and other opisthokonts (S1 Fig),
and used this as reference to identify and categorise potential orthologues in the Trypanoso-
matida (S2 Fig). All candidates identified were categorized into five distinct clades based on
the similarity of each towards the corresponding orthologue in the opisthokonts; a trypanoso-
matid-specific ALDH subfamily, represented by Tb927.6.4210 in T. brucei, emerged along
with ALDH1/2, ALDH3, ALDH4 and ALDH5 subfamilies, indicating evolutionary functional
divergence (Fig 3A). Importantly, Tb927.6.3050 falls into the clade comprising members of the
ALDH3 subfamily that have been linked specifically to the metabolism of fatty acid and aro-
matic aldehydes [29], and thus is designated as TbALDH3 (Uniprot Q583M9).
Greater functional insight was attained from analyzing the TbALDH3 structure by X-ray
crystallography. The structure of HsALDH3A1 [30] (PDB 1AD3) was used as the searching
template to obtain the initial phases of the structure by molecular replacement. In the solved
structure (PDB 5MYP), TbALDH3 appears as a dimer that consists of two monomeric poly-
peptides (S1 Table). As shown in Fig 3B, the monomer structure comprises 485 residues from
A6 to K490, and adopts a canonical ALDH fold that is composed of an N-terminal NAD-
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binding domain, a catalytic domain and an oligomerization domain embracing the second
subunit of the dimer. Several distinct features are also apparent in the structure, including an
extended N-terminus with 15 residues preceding helix α1, a side-extrusion from the catalytic
domain formed by helices α10 and α11 that are bridged by a flexible loop (G297-Q303), and an
C-terminal extension adjacent to the dimerization domain (helix α16, Y477-L489). Interestingly,
this C-terminal structural element strikingly resembles the ‘gatekeeper helix’ that is unique to
FALDHs and is involved in regulating enzyme activity and substrate specificity [31].
Fig 2. Potencies of the phenoxy derivatives upon Tb927.6.3050 RNAi. The compounds are listed in pair according to structural similarity in the functional
groups. The methylamine and carboxylic acid groups are highlighted with dot circles. Ref. stands for reference.
https://doi.org/10.1371/journal.ppat.1006850.g002
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Previously it has been noted that differential localizations of family members can contribute
to the functional divergence in ALDHs [32–37]. By immunofluorescence, we found that
TbALDH3 is predominantly co-localized with glyceraldehyde phosphate dehydrogenase
(GAPDH). The latter is a distinctive marker for glycosomes, a specialised membrane-enclosed
organelle in a few protozoan species including T. brucei, derived from peroxisomes and with
essential metabolic functions (Fig 3C). This result is also supported by a recent quantitative
glycosomal proteomics study that identified TbALDH3 with high confidence [38]. Overall this
evidence strongly suggests that TbALDH3 functions as a glycosomal FALDH.
Aminomethylphenoxy benzoxaboroles can be metabolized by MAO-TbALDH3. Bio-
genic amines, exemplified by neurotransmitters, including serotonin and dopamine, are
Fig 3. TbALDH3, encoded by Tb927.6.3050, is a member of FALDH subfamily. (A) The unrooted phylogenic tree was constructed based on the alignment of all
ALDH orthologues in Trypanosomatida with the Opisthokont orthologues representing all the subfamilies of the ALDH superfamily categorized. Only representative
orthologues are presented for simplicity. See S1 and S2 Figs for the complete data set. Each clade, in which the Trypanosomatida orthologues are identified with a
Opisthokont subfamily, is assigned with the corresponding subfamily number, indicated in black; otherwise in grey. The family members in T. brucei are highlighted
in a larger font with Tb927.6.3050 also in red. Strongly supported nodes (bootstrap proportion>70, Bayesian posterior probability>90) are indicated by a star. (B)
The structure of TbALDH3 in cartoon representation. One subunit of the dimeric assembly is shown for clarity. Secondary structure elements are labeled and
domains are indicated in color. Blue, catalytic domain; red, NAD-binding domain; green, oligomerisation domain. (C) The glycosomal localization of TbALDH3. The
glycosomal localization is represented by the GAPDH signal, and the nucleus by DAPI stain. Scale bar = 1um.
https://doi.org/10.1371/journal.ppat.1006850.g003
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generally metabolized through two sequential enzymatic reactions; amine oxidases (AOs) such
as monoamine oxidase (MAO) are responsible for an amine-to-aldehyde transition in the first
step, while ALDHs in the second step further oxidize aldehyde metabolites into carboxylic
acids [39, 40]. We hypothesized that a similar enzymatic cascade converts aminomethylphe-
noxy compounds into carboxylphenoxy metabolites, in which the first reaction is catalyzed by
an AO, followed by a second oxidation by TbALDH3.
To test this hypothesis, we introduced AN3057 into an in vitro enzymatic cascade reaction,
as shown in Fig 4A, and extracted the metabolites for HPLC-MS analysis. In the absence of
MAOa (two upper panels in Fig 4B), there was no enzymatic conversion of AN3057 (CH3-
NH2) by TbALDH3 as indicated by the unchanged retention time (RT) and the MS profile of
the metabolite compared to the control. The MS m/z of 238 did differ from the theoretical m/z
of 255.08, most likely due to the loss of a hydroxyl group (-OH) (S3 Fig). In contrast, two
major metabolites, M-A1 and M-A2, were detected when both MAOa and TbALDH3 were
present (middle panel in Fig 4B). The RTs of M-A1 and M-A2 were altered in an analogous
manner upon changing the eluent pH from acidic to basic, suggesting that both metabolites
contain an acid moiety (S2 Table). Additionally, the MS profile of M-A1 was identical to
AN2861 (-CO2H) (S3 Fig), but different from M-A2, in which the boron atom was very likely
lost as suggested by the changes in both elemental composition and isotope pattern, giving rise
to a RT different from M-A1 (Fig 4B, S3 Fig). Interestingly, two metabolites (M1, M2) were
generated with distinct MS profiles from either AN3057 (-CH2NH2) or AN2861 (-CO2H)
when TbALDH3 was absent (lower panel in Fig 4B). Upon changing the eluent pH, there was
no significant change in RT observed with M1 and M2, indicating that both of these metabo-
lites are likely uncharged (S2 Table). Moreover, the difference in MS between M1 and M-A1
correlates well with the transition from aldehyde (-CHO) to carboxylic acid (-CO2H), as well
as M2 and M-A2 (Fig 4B and S3 Fig), suggesting it is highly likely that M1 and M2 are the alde-
hyde precursors of the carboxylic acids M-A1 and M-A2 respectively. These data collectively
support the notion that MAOa-TbALDH3 can metabolize the aminomethylphenoxy deriva-
tives in a stepwise manner, i.e. the methylamine group in the structure is first converted by
MAOa into an aldehyde, and then is further metabolized into a carboxylic acid by TbALDH3.
It is also supported by the results with another isomer, AN3054, albeit with distinct kinetics
that may reflect the variation in the efficiency of conversion (S4 Fig).
Next, we used the aldehyde and carboxylate metabolites generated as specific chemical
probes to directly address if the trypanocidal activity of the aminomethylphenoxy benzoxabor-
oles is dependent on the function of this enzymatic pathway. We reasoned that if the enzy-
matic activity was essential for potency, silencing TbALDH3 by RNAi would lead to decreased
potency for the parental compound (-CH2NH2) or the aldehyde metabolite (-CHO) but the
carboxylate metabolite would remain unaffected. As shown in Fig 4C, substantial reductions
in potency were observed for the parental compound (ΔEC50135) and for the aldehyde
metabolite (ΔEC5090), in clear contrast to static potency for the carboxylate metabolite
(ΔEC501.5). Therefore, TbALDH3 action, as part of an AO-TbALDH3 enzymatic pathway, is
indeed essential for trypanocidal activity of the aminomethylphenoxy benzoxaboroles.
Molecular insights into the oxidation of the aldehyde metabolites by
TbALDH3
To understand the reaction catalyzed by TbALDH3 at molecular level, we obtained crystals of
the aldehyde-NAD-TbALDH3 complex. A micro-reaction chamber (S5 Fig) was designed to
serve as a physical barrier between the two reactions as well as to minimize the reverse reac-
tion; meanwhile, a cysteine to serine mutation (C259S) was introduced in TbALDH3 to entrap
Aminomethyl benzoxaborole activation enzymatic pathway
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Fig 4. AN3057 is metabolized by MAO-TbALDH3. (A) Schematic view of the enzymatic reactions with MAOa-TbALDH3 in metabolizing AN3057. (B)
HPLC-MS identification of AN3057-derived metabolites from the MAO-TbALDH3 pathway. HPLC peaks are indicated with corresponding retention time (RT)
under acidic condition, m/z of ion precursors identified in MS, and proposed structural formula. See S2 Table for the RTs with acidic eluent or basic eluent; S3 Fig
for the detailed MS data. (C) The potency (EC50) of AN3057 and derived metabolites in T. brucei. The change in EC50 upon TbALDH3 RNAi is presented for each
molecule with the key moiety illustrated, i.e., methylamine, aldehyde, and carboxylic acid.
https://doi.org/10.1371/journal.ppat.1006850.g004
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the hyperactive aldehyde metabolites by abolishing the nucleophilic attack on the carbonyl car-
bon of the aldehyde. The resulting crystals are isomorphous to the apo-TbALDH3 crystals and
the structure was solved at 2.5 Å (PDB 5NNO). As illustrated in Fig 5A, the NAD cofactor is
located in an extended pocket rendered by a Rossmann fold [41]. There are two hydrogen
bonds formed between E365 and the hydroxyl groups of the ribose of the nicotinamide, estab-
lishing the key interactions between NAD with TbALDH3 in addition to an H2O-bridge that
connects the carboxylate group of the nicotinamide to Y444 and T200. Interestingly, similar
topological arrangements have been proposed as part of the catalytic mechanism for ALDH.
In this structure, the benzaldehyde benzoxaborole substrate exhibits distinctive electron den-
sity (S6 Fig), being nestled into the substrate funnel and adjacent to the nicotinamide (Fig 5B).
Specifically, in the catalytic pocket, its aldehyde group directly contacts the catalytic residue
(C259S), and also connects to N128, a residue whose counterparts in other ALDHs are involved
in the catalytic activity by directing the carbonyl carbon towards the nucleophilic carbon on
the nicotinamide [42, 43]. Noticeably, the position of the substrate is relatively flexible as indi-
cated by the B-factor (S1 Table). There is an additional interaction between the substrate and
TbALDH3, which is mediated by the hydrogen bond between the hydroxyl group of the hemi-
boronic ring in the substrate and a side-chain conformer of R473 in TbALDH3, proximal to the
gatekeeper helix of the adjacent protomer (Fig 5B). In contrast, the boron atom remains in tri-
gonal planar configuration, therefore capable of forming stable adducts with the potential tar-
gets, which suggests that the aldehyde metabolites serve as the substrates of TbALDH3 rather
than the enzyme inhibitors as described in other cases [11, 13, 20].
The enzymatic specificity of TbALDH3 towards the aldehyde metabolite was further deter-
mined by superimposing the structure onto two other ALDH3 subfamily member structures,
HsALDH3A2 and RnALDH3A1 (Fig 5C; see S7 Fig for the sequence alignment). The C-termi-
nal ‘gatekeeper’ helix in HsALDH3A2, absent in RnALDH3A1, has been shown to be involved
in defining its substrate specificity by partially occluding the substrate entrance from the ‘sub-
strate funnel’. Interestingly, a similar structure is also defined in TbALDH3, although it is dis-
tant from the ‘substrate funnel’, probably imposing less restriction on the substrates (Fig 5B
and 5C). This structural element in TbALDH3 appears to be held in position via the hydrogen
bond between K481 and the backbone carbonyl of F474; highly conserved among human
FALDHs (S8 Fig), and serving as a mechanical hinge to support the activity of FALDHs. A
point mutation in HsALDH3A2 (K447E), equivalent to the K481E in TbALDH3, leads to a defi-
cient enzymatic activity and is genetically linked to Sjögren–Larsson Syndrome [44]. More
importantly, in the superimposition (Fig 5B), the benzaldehyde-benzoxaborole substrate can
be accommodated by TbALDH3 and HsALDH3A2, but encounters steric clashes with
RnALDH3A1, indicating that the unique topological arrangement in the substrate funnel of
FALDHs such as HsALDH3A2 and TbALDH3 determines the substrate specificity besides the
positioning of the C-terminal ‘gatekeeper’ helix. This also raises the possibility that the conver-
sion of the aldehyde metabolites into carboxylic acids could also occur in the host, as the struc-
tural similarity suggests that human FALDHs, like HsALDH3A2, are likely to possess a
substrate specificity similar to TbALDH3.
Host-derived SSAO is the dominant oxidase mediating
aminomethylphenoxy benzoxaborole metabolism
The MAO-like enzymatic activity of the AO-TbALDH3 pathway remained undefined in vivo,
considering the fact that neither genetic nor biochemical evidence supports the presence of
such activity in Trypanosoma [45]. We postulated that the host provides this enzymatic activ-
ity, which is supported by documented AO activity in animal plasma [46–48]. Fetal bovine
Aminomethyl benzoxaborole activation enzymatic pathway
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serum (FBS) is the only host-derived metabolically active component in our parasite culture
system, and is the most likely source. To test this, we first analyzed the metabolism of AN3057
using an enzymatic cascade in vitro, composed of FBS and TbALDH3, by HPLC-MS (Fig 6A).
The chemical transitions revealed resemble those through the MAOa-TbALDH3 pathway
(Fig 4). No significant metabolic changes were detected with AN3057 in the absence of FBS,
although the same loss of a hydroxyl group (-OH) occurred as observed previously with
MAOa. Conversely, in the presence of both FBS and TbALDH3, two acidic metabolites (F-A1,
F-A2) were identified, with F-A1 sharing the same MS profile with AN2861 and F-A2 sub-
jected to the loss of boron (S9 Fig). Furthermore, when TbALDH3 was absent, AN3057 was
metabolized via FBS into two metabolites (F1 and F2), both of which are suggested as similar
benzaldehyde entities distinguished primarily by the boron in the structure (S9 Fig). In sum-
mary, AN3057 is converted by FBS first into the aldehyde metabolites (F1, F2), which are then
further metabolized by TbALDH3 to the carboxylate metabolites (F-A1, F-A2). The metabolic
pathway revealed here very likely mirrors the host-pathogen encounter in the host vascular
system. To further validate this point, we examined the relative potencies of the metabolites,
generated by the FBS-TbALDH3 in vitro cascade reactions, upon silencing TbALDH3 by
Fig 5. Structural insight into interactions between the aldehyde metabolites and TbALDH3. (A) TbALDH3 catalytic site. All key residues are in stick
representation, while NAD and AN3057-aldehyde are shown with electron density (blue chicken wire), in which non-carbon atoms are marked in color, oxygen in
red, nitrogen in blue, and phosphorus in orange. Potential hydrogen bonds are depicted as black dashed lines; selected water as blue spheres. (B) The comparison of
substrate binding funnel between TbALDH3, HsALDH3A2 and RnALDH3A1. The cross-section structures are depicted from a top view with indicated features.
NAD and AN3057-aldehyde are shown in solid stick representation with TbALDH3, while transparent superimposed to HsALDH3A2 and RnALDH3A1. (C) The
structural superposition of TbALDH3 with mammalian homologues, RnALDH3A1 (Rat, blue) and HsALDH3A2 (Human, black). Two orientations are presented
with indicated features. TbALDH3- RnALDH3A1 alignment: 1.4Å (rmsd); 445 (Cα-atoms); 55 (Z-score); 47% (identity). TbALDH3-hALDH3A2: 1.8Å (rmsd); 454
(Cα-atoms); 54 (Z-score); 47% (identity).
https://doi.org/10.1371/journal.ppat.1006850.g005
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Fig 6. SSAO-TbALDH3, contributed by both host and parasites, metabolizes the aminomethyl-benzoxaboroles. (A) HPLC-MS identification of AN3057 and
derived metabolites from the FBS-TbALDH3 pathway. HPLC peaks are indicated with corresponding retention time (RT), m/z of ion precursors identified in
MS, and proposed structural formula. See S9 Fig for the detailed MS data. (B) The potency (EC50) of AN3057 and derived metabolites in T. brucei. The change in
EC50 upon TbALDH3 RNAi is presented for each molecule with the key moiety illustrated, i.e., methylamine, aldehyde, and carboxylic acid. (C) SSAO
contributes to the AO activity in FBS. FBS-derived AO activity is represented by the luminescence intensity from Luciferin, the generation of which is coupled to
the aldehyde-carboxylic acid conversion. The chemical inhibitors are listed as follows, Semicarbazide (Semi), 2-Bromopropylamine hydrobromide (Bromo),
Tetraphenylphosphonium (TPP), N,N-Diethyldithiocarbamate (DDC), Mexiletine (Mexi) and Ammonium tetrathiomolybdate (ATTM). (D) The potency (EC50)
of AN3057 in T. brucei upon SSAO inhibition. Prior to the assay, the complete media were incubated with indicated concentrations of inhibitor for 4 hours.
https://doi.org/10.1371/journal.ppat.1006850.g006
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RNAi. As shown in Fig 6B, with both the methylamine parent and aldehyde metabolites, the
potency was significantly compromised following the RNAi. In contrast, no significant change
in potency was observed with the carboxylate metabolites. Therefore, an FBS-TbALDH3 path-
way can serve as a metabolic route through the host and the parasite for activating the amino-
methylphenoxy benzoxaboroles.
Primary amine oxidases are generally classified into two major groups that are distin-
guished by the co-factor-dependent catalytic mechanism; one group is dependent on Flavin
Adenine Dinucleotide (FAD) and represented by MAOa, while the second group, exemplified
by Semicarbazide-Sensitive Amine Oxidase (SSAO), on copper-quinone [49, 50]. This bio-
chemical feature differentiates the enzyme sensitivity to inhibitors that are specifically target-
ing the respective co-factors. Following this notion, we chose a fluorescence-reporter
enzymatic assay to characterize the AO activity in FBS with a panel of specific AO inhibitors.
As shown in Fig 6C, the enzymatic activity was exclusively sensitive to the SSAO inhibitors,
particularly semicarbazide (Semi) and bromoethylamine (Bromo), and remained unaffected
by MAO inhibitors, thus confirming that SSAO provides the predominant AO activity in FBS.
More importantly, when we introduced semicarbazide into the trypanosome cultures, the
potency of AN3057 was significantly compromised in a dose-dependent manner (Fig 6D),
indicating the SSAO deamination activity derived from the host is critical for activating the
aminomethylphenoxy benzoxaboroles as potent trypanocidals. Therefore, we identified the
SSAO as the primary metabolic enzyme in the host intravascular system for metabolizing the
chemical compounds containing primary amines via the oxidative deamination.
Discussion
Benzoxaboroles have opened new pharmaceutical opportunities by combining unique chemi-
cal properties of the benzoxaborole core structure with a repertoire of structurally diverse sub-
stituents. This gives rise to a wide range of chemical entities of pharmaceutical interest that
potentially act via diverse mechanisms in targeting various medical conditions. So far, the
effort in understanding the MoA has been focused on identifying potential functional targets,
with which the boron atom, as well as additional functional groups of the compounds, form
stable interactions. For example, fungal or bacterial Leucyl-tRNA forms covalent bonds
through the tRNA’s adenosine with the boron [16, 20]; CPSF3, an essential RNA metabolism
factor in several protist parasites, is targeted primarily by the boron and the carboxylate group
in AN3661 that form non-covalent bonds with the surrounding catalytic structures [11, 13].
However, a systemic understanding of the reciprocal actions between benzoxaboroles and tar-
geted pathogens is lacking in general, particularly regarding the mechanisms underlying drug
uptake and metabolism.
Here we exploited a genome-scale loss-of-function screen to unravel the complex interplay
between structurally diverse benzoxaboroles and T. brucei as a pathogenic model. Part of the
initial identifications suggested a specific SAR between the function conferred by an individual
gene and aminomethylphenoxy derivatives, mediated by the methylamine moiety shared by
the compounds. This gene encodes a protein, TbALDH3 that potentially functions as a trypa-
nosomal FALDH based on our crystallographic and biochemical characterizations. More
importantly, further evidence indicates that TbALDH3 contributes to an oxidative deamina-
tion enzymatic pathway that is initiated by a host AO activity and is required to achieve full
potency of aminomethylphenoxy benzoxaboroles as trypanocides (Fig 7). Overall, this finding
brings a drug metabolism perspective to our understanding of the MoA for benzoxaborole-
based pharmaceutical entities, as well as highlights the possibility of similar metabolic path-
ways present in broader pathological contexts. Indeed, alternative routes could be constructed
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by divergent host AOs and pathogen-derived ALDHs, metabolizing structurally diverse com-
pounds containing an amine moiety. Interestingly, a novel chemical route has been proposed
for improving the potency of the antibiotics against Gram-negative pathogenic bacteria [51].
One of the key aspects was to introduce an amine group into the candidate molecules, result-
ing in effective drug accumulation in the pathogen, which implies more general applications
for the drug metabolism mechanism uncovered here. We suggest that the potential exploita-
tion of similar metabolic pathways on aminomethyl-containing drugs could be of significant
value.
We also demonstrated that the carboxylate metabolites of the compounds exhibit the pri-
mary trypanocidal activity, although the same chemical entities, if applied directly, are less
potent than the methylamine isomeric compounds and corresponding aldehyde metabolites.
This lower potency with the carboxylate-containing benzoxaboroles is likely due to a less effi-
cient drug uptake, as these compounds are negatively charged at neutral pH and hence might
exhibit lower membrane permeability than uncharged aldehyde metabolites derived from
methylamine pro-drugs. Noticeably, carboxylate benzoxaborole derivatives remain active as
potent anti-parasitic candidates against Plasmodium falciparum and Toxoplasma gondii [11,
13]. Therefore, the drug metabolism mechanism revealed here can be exploited to improve the
drug potency of these candidate compounds by replacing the carboxylate group with a methyl-
amine. It would be also interesting to explore the uptake mechanism of these carboxylate ben-
zoxaborole derivatives.
Our work indicates that the second oxidative reaction catalyzed by TbALDH3 likely occurs
in glycosomes, therefore raising two possibilities of subcellular targeting mechanisms for the
carboxylate benzoxaboroles as effective drugs, i.e. being either glycosomal or in alternative
subcellular compartments. Nevertheless, the carboxylate derivatives such as AN2861 exhibit
potent trypanocidal activities, independent of SSAO-TbALDH3 metabolic conversion. These
data together suggest that the carboxylate benzoxaboroles are capable of overcoming the
restriction, imposed by the negative charge of the compounds, on membrane permeability at
both cellular and subcellular levels. This notion is also supported by our additional observation
Fig 7. Model for aminomethylphenoxy benzoxaboroles metabolism in vivo. In the host, the aminomethylphenoxy benzoxaboroles are first oxidized by SSAO in the
intravascular system. The resulting aldehyde metabolites are taken up by the parasites, and further oxidized into carboxylic acids that give rise to the final active
trypanocides. The activation of the compounds requires both enzymatic activities in the host and parasites, with the loss of drug potency when either enzymatic activity
is compromised. The key chemical moieties undergoing biochemical transitions through this process are highlighted with dotted boxes.
https://doi.org/10.1371/journal.ppat.1006850.g007
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where there was no difference in the metabolomic profiles of parasites treated with AN3057 or
with acoziborole (S3 Table), suggesting that similar ultimate impacts on the parasite targets are
likely shared by structurally diverse benzoxaborole derivatives.
In addition to the oxidative deamination by AO-TbALDH3, we also observed an oxidative
deboronation process, which has also been described elsewhere, especially in host plasma, for
divergent classes of benzoxaboroles, where it accounts for a compromise in the efficacy of
these compounds [52, 53]. Our observation raises a possibility that the oxidative enzymes in
plasma such as AOs could be responsible for this oxidative deboronation reaction, therefore
providing a possible route for improving the efficacy of benzoxaboroles in general. It also sug-
gests the parasite culture system as a credible model in understanding drug metabolism
through host and intravascular parasites. Meanwhile, the aldehyde metabolites derived from
the amine-containing pro-drugs are relatively stable, allowing us to analyze them by MS and
also to extract them for probing the activity of TbALDH3 directly in the parasites. It actually
reflects the general feature of the ketone and aldehyde metabolites in various biological and
pathological contexts such as diabetes and alcoholism[54].
Although further work is required to define the physiological functions of TbALDH3, it is
reasonable to speculate that long chain fatty aldehydes are the most likely substrates for
TbALDH3, based on phylogenetic and structural analyses, as well as a glycosomal localization
of the enzyme. However, little is known in general about the role of glycosomal lipid metabo-
lism in the adaptation of trypanosomes to the host environment, nor the potential roles of
ALDHs in fatty acid metabolism in trypanosomes. Interestingly, adipose tissue has been
recently demonstrated as a host reservoir for T. brucei [55], suggesting that further under-
standing of TbALDH3 and related FALDHs could provide unique insight into host-parasite
interactions and compartmentalization of metabolic functions.
Materials and methods
RIT-seq and data analysis
Genetic determinants of drug resistance were identified using a T. brucei RNAi library screen
as previously described [26]. Briefly, the library was grown under RNAi-inducing conditions
(tetracycline, Tet at 1 mg.ml-1) 24 h prior to benzoxaborole drug-selection at 1.5~2xEC90.
Through the screening, cultures were maintained and supplemented with fresh drug before
extracting DNA from the drug-resistant population once it was established. RNAi target frag-
ments within the population were amplified by PCR using LIB2f and LIB2r primers and the
collective products were then subjected to high-throughput sequencing at BGI (The Beijing
Genome Institute). The workflow for sequencing was as follows; the sequence libraries were
constructed with the PCR products fragmented to ~300 bp and subjected to Illumina
HiSeqTM4000. Reads were mapped to the T. brucei 927 reference genome (v6, tritrypdb.org)
with Bowtie 2 [56] using the parameters: very-sensitive-local–phred33. Alignment files were
manipulated with SAMtools [57] and a custom script [26], and data were further assessed
using the Artemis genome browser [58].
Drug potency (EC50)
EC50 was determined by exposing cells to the test compound at serial dilutions (2X or 4X as
indicated in the corresponding data) with the highest concentration at 10 μM unless specified
otherwise. The assays were conducted in 96-well plate format with three replicates for each
sample and a non-treatment control in parallel [59]. The parasites were seeded at 1X104 cells/
ml and cultured for 72 h before adding resazurin. After 6h of incubation with resazurin, the
fluorescence from resorufin was measured with a Gemini Fluorescent Plate reader (Molecular
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Devices) at an excitation wavelength of 530 nm, an emission wavelength of 585 nm and a filter
cut-off of 570 nm. Each dataset shown is representative of three independent experiments
(n = 3); in the case of RNAi, two independent RNAi clonal cultures were analysed.
Plasmid construction and cell lines
For expressing recombinant proteins, the complete Tb427.06.3050 (TbALDH3) coding
sequence was PCR amplified from genomic DNA and cloned into a modified pET27b vector
(Novagen) creating pET27bTbALDH3. The plasmid produces TbALDH3 with a N-terminal
hexa-histidine-tag followed by a tobacco etch virus (TEV) protease cleavage site. Catalytic cys-
teine to serine (C259S) mutation was generated by site directed mutagenesis using the Quik-
change protocol (Stratagene). For RNAi, in brief, a gene-specific target sequence was selected
through RNAit [60] and introduced into 2T1 cells using the pRPaiSL vector [61]. Upon Tet-
induction, dsRNAs were generated from the target sequence and the sequence-dependent
RNAi was initiated in the transformed cells. For tagging the native locus, a sequence encoding
a 6xMyc epitope was introduced into the native loci of Tb427.06.3050 using the pNATxTAG
vector, resulting in the strain expressing TbALDH3 with a C-terminal epitope. The integrity of
all constructs was verified by sequencing. See S4 Table for the details of constructs and the
primers for cloning. All the transformed T. brucei bloodstream strains were established and
maintained as previously described [61].
Phylogenetic analysis
Sequences of putative aldehyde dehydrogenases were retrieved from a BLASTp [62] search using
Homo sapiens ALDH proteins as query against the genomes of the selected Opisthokont and
Trypanosomatida species (BLOSUM62, Existence: 11 Extension: 1 Conditional compositional
score matrix adjustment). The subsequent hits were analysed and outliers excluded from the
phylogenetic assembly based on protein alignment generated using EMB-EBI Clustal Omega.
The curated list of proteins was again analysed with Clustal Omega and manually edited to
remove the poorly aligned regions of the C and N terminus. Phylogenetic reconstructions
were generated using PhyML [63] and MrBayes [64] using the default parameters with a 1000
bootstrapping and 800000 generations, respectively. Resulting trees were visualized using Fig-
Tree (http://tree.bio.ed.ac.uk/software/figtree/). At least two members of each clade in the
individual Opisthokont tree were selected and aligned with a representative of the Leishmania
sp., the Leptomonas sp., the African and the American Trypanosoma sp. proteins for each clade
to reconstruct the phylogeny of aldehyde dehydrogenases. No ALDH6, ALDH16 or ALDH18
orthologues were identified in Trypanosomatida and their branches have been omitted from
the Trypanosomatida-Ophistokont tree for simplification; ALDH families 7, 8 and 9 are
shown in grey for the same reason. See S5 Table for the details of the species and the sequences
with accession numbers.
Recombinant protein expression and purification
Recombinant TbALDH3 protein was obtained by cultivating freshly transformed E. coli BL21
(DE3) Rosetta Gami 2 (Novagen) in a starter culture of Luria-Bertani (LB) medium in 20 mL,
supplemented with 50 μg/mL of kanamycin and 15 μg/mL of chloramphenicol. 5 mL of the
starter culture was then inoculated with the selective LB culture (4 L) with 1 mM magnesium
chloride and 0.5 mM calcium chloride, grown at 37˚C in 5 L Erlenmeyer flasks. OD600 was
measured until it reached 0.6–0.8, at which point expression was induced with 1 mM IPTG
(isopropyl-β-D-thiogalactopyranoside) and the culture incubated overnight at 25˚C. The cells
were harvested by centrifugation at 5000 g for 30 minutes at 4˚C and were resuspended in
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buffer A (50 mM sodium phosphate pH 7.8, 300 mM sodium chloride, 10% glycerol) along
with a protease inhibitor tablet (Roche). The cell-buffer A was passed through a pressure cell
homogeniser (SPCH-10, Stansted), supplemented with 25 mM imidazole and passed through
a 0.45 μm filter. A 1 mL CV (column volume) His-Trap HP column (GE Healthcare) charged
with Ni2+ was calibrated by 4 CV washes with buffer B (50 mM sodium phosphate pH 7.8, 25
mM imidazole, 300 mM sodium chloride, 10% glycerol) after which the sample was loaded
and fractions collected over a linear increase in imidazole concentration (25–250 mM over 18
CV). Fractions containing the eluted recombinant TbALDH3 protein were combined and
concentrated in a spin concentrator (Millipore) exchanging the buffer to buffer A and the sam-
ple incubated overnight with His-tagged TEV protease (molar ratio of 1:20 TEV:recombinant
protein). The sample was passed through a His-Trap HP column previously equilibrated with
a buffer A, to separate cleaved enzyme from non-cleaved protein and the TEV protease itself.
Fractions containing TbALDH3 were concentrated and chromatographed through a 24 mL
CV Superdex75 GL (HR 10/300, GE Healthcare) size exclusion chromatography column equil-
ibrated with buffer A. The size exclusion chromatography columns had been calibrated with
molecular mass standards (thyroglobulin, 670 kDa; gamma-globulin, 158 kDa; serum albumin,
67 kDa; ovalbumin; 44 kDa, myoglobin, 17 kDa; vitamin B12, 1 kDa). Fractions containing
purified TbALDH3 were combined, concentrated and used in crystallisation trials. The yield
of TbALDH3 was estimated on the basis of theoretical molar extinction coefficients at 280 nm
of 42860 M-1 cm-1, respectively, calculated using the software VectorNTI (Invitrogen).
Crystallography
TbALDH3 crystals, maximum dimension 0.5 mm, were obtained in five days by sitting-drop
vapour diffusion at 20˚C in 3 μL drops in the ratio of 1:1 protein solution (20 mg/mL
TbALDH3 in 50 mM sodium phosphate pH7.8, 300 mM sodium chloride, 10% glycerol) to
reservoir condition (100 mM Bis-Tris pH 5.5, 0.2 M LiSO4, 25% PEG3350). For co-crystallisa-
tion with the aldehyde form of AN3057 the purified catalytically inactive TbALDH3C259S was
concentrated to 27 mg/ml in buffer A supplemented with 2 mM NAD+, 2 mM MgCl2 and dia-
lysed (3500 MWCO) for 14 h at RT against the same buffer containing 10 μM MAO-A (Sigma
Aldrich) and 1 mM AN3057 using a homemade microdialysis device, then used in the same
crystallization setup as before. TbALDH3 crystals, though of good appearance, displayed dif-
fraction indicating the presence of multiple crystalline components. This problem was more
dominant in the co-crystals and numerous crystals had to be screened to identify a crystal with
twinning-properties down to acceptable levels.
Crystals were harvested using a glycerol or LV-oil (MiTeGen) cryoprotectant, flash frozen
in liquid nitrogen and characterised in-house with a Rigaku MicroMax 007HF generator
equipped with VariMax VHF optic, and a Saturn944 HG+ CCD detector. The data were
indexed and merged using XDS [65] and SCALA [66], respectively. The crystals displayed the
space group P1211. The crystal structure of the wild-type apoprotein was solved to 1.95 Å
using the MR protocol of Auto-rickshaw [67] using a 432 residues search model built using
PHYRE2 [68]. Density modification was performed using PIRATE [69], as implemented in
the CCP4 suite of programs [70], and the model was extended to 920 residues with ARP/
wARP [71]. Refinement with Refmac5 [72] resulted in Rwork and Rfree of 0.19 and 0.24, respec-
tively. This model was inspected, along with electron density and difference density maps,
adjusted and extended to 973 residues using COOT [73]. Translation/Libration/Screw (TLS)
refinement [74] in Refmac5 with multiple rounds of electron and difference density map
inspection, model manipulation and the inclusion of water molecules, dual conformers and
glycerol completed the refinement. The apoprotein structure served as a search model to phase
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native data collected from the isomorphous co-crystals to 2.5 Å by molecular replacement with
PHASER. Rounds of model adjustment using COOT, interspersed with rounds of Refmac5
intensity based twin-refinement calculations, the addition and refinement of AN3057 alde-
hyde, NAD, water molecules, and inclusion of multiple conformers completed the refinement.
Geometrical restraints for the AN3057 aldehyde intermediate were generated using the Grade
Web Server (http://grade.globalphasing.org).
MOLPROBITY [75] and COOT were used to monitor model geometry during TbALDH3
refinement. Figures were prepared using PyMOL (Schro¨dinger LLC). The DALI server was
used to search the PDB for structural homologues and structural superpositions were per-
formed using DALILITE [76]. Multiple sequence alignments were calculated using CLUS-
TALW2 [77] and edited using ALINE [78]. Crystallographic statistics are presented in S1 Table.
Chemicals and antibodies
AN3057, (4-(1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-5-yloxy)phenyl) methanaminium
chloride, was synthesized as described [79], to a 4.78 mmol solution of 1.2 g of 4-(1-hydroxy-
1,3-dihydrobenzo[c][1,2]oxaborol-5-yloxy) benzonitrile in EtOH (150 mL) under N2 was
added Pd/C (10 wt.%, 0.178 g). The reaction mixture was hydrogenated for 26.5 hours using a
H2 balloon at room temperature with stirring. The mixture was filtered, rotary evaporated and
purified by silica gel column eluted with MeOH containing 0.6% volume NH4OH (3 mL 28–
30% NH4OH to 500 mL MeOH). The white solid obtained was dissolved in water (80 mL) and
6N HCl (2 mL) was added, filtered and the filtrate was lyophilized to give the desired salt
(4-(1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-5-yloxy)phenyl)methanaminium chloride as
white solid (0.93 g, 3.19 mmol, yield 66.7%). M.p. > 250˚C. 1H-NMR (DMSO-d6, 300 MHz): δ
9.18 (s, 1H), 8.43 (br. s, 3H), 7.74 (d, J = 8.1 Hz, 2H), 7.52 (d, J = 8.7 Hz, 2H), 7.08 (d, J = 8.7
Hz, 1H), 6.98–6.94 (m, 2H), 4.91 (s, 2H) and 3.99 (br. q, J = 4.8 Hz, 2H) ppm. Purity (HPLC):
94.9% at 254 nm. MS: m/z = 256 (M+1, ESI+) and m/z = 255 (M-, ESI-). The method is sum-
marized in S10 Fig. AN2861 was described by Yong-Kang et al. [80], while AN3054, AN3056,
AN3330, AN3410 were described by Akama et al. [81]. The chemicals purchased from Sigma
are as follows, Tetracycline hydrochloride (T7660), Clorgyline (M3778), Semicarbazide
(S2201), Tetraphenylphosphonium chloride (218790), Sodium diethyldithiocarbamate trihy-
drate (D3506), 2-Bromoethylamine hydrobromide (B65705), Mexiletine hydrochloride
(M2727), Ammonium tetrathiomolybdate (323446), Resazurin (R7017), anti-Myc
(commercial).
HPLC-MS
Samples were analyzed on a Waters Xevo Q-TOF Mass Spectrometer coupled to a Waters
Acquity UPLC system using a Waters BEH C18 column 50x2.1mm 1.6 μm. Analysis was done
in either acidic (A: H2O + 0.1% formic acid, B: ACN + 0.1% formic acid) or basic eluents (A:
H2O + 0.1% NH3 solution, B: ACN + 0.1% NH3 solution). The same gradient was used with
both types of eluent: 98% A for 0.5 min then linear gradient to 65% A (3.5 min) then to 5% A
in 1 min, gradient held for 1 min before a step change back to the to the starting conditions
and an equilibration time of 1 min (total run time 7 min).
The mass spectrometer was operated in both positive (Capillary Voltage 2.3 kV) and nega-
tive mode (Capillary Voltage 1.5 kV). Source temperature and desolvation gas temperatures
were constant at 120˚C and 500˚C respectively. In MS operation, spectra were acquired every
0.2 s over a 50–1000 amu range.
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Amine oxidase activity assay
MAO-Glo assay (Promega, V1401) was applied to determine MAO and SSAO activities
respectively according to manufacturer’s instructions. Recombinant human MAO A (Sigma,
M7316) was included as the positive control, and the assay was conducted with following the
optimized protocol [82].
Immunofluorescence
TbALDH3 localization was determined using a native C-terminal 6xMyc epitope fusion. Sam-
ples were prepared as previously described. Antibodies were used at the following dilutions:
rabbit anti-myc epitope IgG (Santa Cruz Biotechnology Inc.) at 1:500, and mouse anti-
TbGAPDH (a kind gift from M.A.J. Ferguson, Dundee) at 1:1000. Secondary antibodies (Life
Technologies) were Alexa Fluor 568 conjugated anti-rabbit IgG (1:1000) and Alexa Fluor 488
conjugated anti-mouse (1:1000). Coverslips were mounted using Prolong Gold mounting
medium supplemented with 4’,6-diamidino-2-phenylindole (DAPI) (Life Technologies). The
cells were examined on a Zeiss Axiovert 200M microscope and images captured with a Axio-
Cam MRm camera. Digital Images were captured and processed using Zen Pro software
(Zeiss) and Adobe Photoshop CS3 (Adobe Systems Inc.).
Metabolite extraction and analysis
Metabolite extractions were performed as previously described [83]. Briefly, bloodstream form
cells were treated with 5xEC50 of drug in HMI-9 for the time required for growth to be inhib-
ited (6 hours for AN5568, 8 hours for AN3057). 1 x 108 cells were centrifuged and extracted
for one hour, shaking in 200 μL UPLC grade chloroform:methanol:water (1:3:1) on ice. Sam-
ples were centrifuged and stored at -80˚C before being run on a QExactive mass spectrometer
(Thermo) after separation on a zic-pHILIC column (Sequant) according to previously pub-
lished methods. Raw data were filtered and aligned and annotated using the Orbiwarp algo-
rithm in PiMP (http://polyomics.mvls.gla.ac.uk/) was used to match masses and retention
times to authentic standards, to provide annotations and to perform statistical analyses.
Supporting information
S1 Fig. Phylogenetic analysis of ALDH family in Opisthokont. Each clade is labelled with
the corresponding subfamily number. All human orthologues are highlighted in bold. The
nodes with significant bootstrap value (>0.6) and Bayesian posterior probability (>90%) are
indicated with stars.
(PDF)
S2 Fig. Phylogenetic analysis of ALDH family in Trypanosomatida. Each clade is assigned
in reference to the Opisthokont subfamilies, and labelled with the corresponding subfamily
number identified with. The nodes with significant bootstrap value (>0.6) and Bayesian poste-
rior probability (>90%) are indicated with stars. The family members in T. brucei are
highlighted in a larger font with Tb927.6.3050 also in red.
(PDF)
S3 Fig. MS spectrums of AN3057, AN2861 and AN3057-derived metabolites from MAOa-
TbALDH3. (A) MS spectrums of the ion precursors from either AN3057 or the metabolite
from AN3057+TbALDH3. The [M+H]+ ion at m/z 239.0 was identified with both, indicating
no change in structure. (B) MS spectrums of the ions precursors from either AN2861 or the
metabolites from AN3057+MAOa+TbALDH3. The [M-H]- ion at m/z 269.0 was identified
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with both AN2861 and M-A1 metabolite, indicating an identical structure, which is consistent
with detecting the [M+H]+ ion at m/z 271.0 from M-A1. The [M-H]- ion at m/z 259.0 was
identified with M-A2 metabolite, resulted from the loss of boron, consistent with detecting the
[M-H2O]+ ion at m/z 243.0 from M-A2. (C) MS spectrums of the ions precursors from the
metabolites derived from AN3057+MAOa. The [M+H]+ ion at m/z 255.0 was identified with
M1 metabolite, suggesting a methylamine- aldehyde conversion occurred. The [M+H]+ ion at
m/z 245.0 was identified from M2, indicating the loss of boron, consistent with detecting the
[M-H]- ion at m/z 243.0.
(PDF)
S4 Fig. HPLC-MS analysis of AN3054-derived metabolites from MAOa-TbALDH3. (A)
HPLC peaks are indicated with corresponding retention time (RT), m/z of ion precursors
identified in MS, and proposed structural formula. See S5 Fig for the detailed MS data. (B) MS
spectrums of the ion precursors from either AN3054 or the metabolite from AN3054+-
TbALDH3. The [M+H]+ ion at m/z 239.0 was identified with both, indicating no change in
structure. (C) MS spectrums of the ions precursors from either AN3330 or the metabolites
from AN3054+MAOa+TbALDH3. The [M-H]- ion at m/z 269.0 was identified with both
AN3330 and M-A1 metabolite, indicating an identical structure, which is consistent with
detecting the [M+H]+ ion at m/z 271.0 from M-A1. The [M-H]- ion at m/z 259.0 was identified
with M-A2 metabolite, resulted from the loss of boron, consistent with detecting the
[M-H2O]+ ion at m/z 243.0 from M-A2. (d) MS spectrums of the ions precursors from the
metabolites derived from AN3054+MAOa. The [M+H]+ ion at m/z 255.0 was identified with
M1 metabolite, suggesting a conversion from methylamine-aldehyde occurred. The [M+H]+
ion at m/z 245.0 was identified from M2, indicating the loss of boron, consistent with detecting
the [M-H]- ion at m/z 243.0.
(PDF)
S5 Fig. Microdialysis device for binding the enzymatically generated TbALDH3 substrate.
A 3.5 kDa dialysis membrane separates the two reservoirs allowing the diffusion of the benzal-
dehyde-benzoxaborole intermediate once formed by MaoA (lower reservoir) and subsequent
binding by the catalytically inactive TbAlDH3 C259S mutant.
(PDF)
S6 Fig. Fo–Fc omit map contoured at 2.0 σ (green chicken wire) and interactions for NAD
+ and the AN3057-aldehyde ligand bound to TbALDH3. All key residues are in stick repre-
sentation, in which non-carbon atoms are marked in color, oxygen in red, nitrogen in blue,
and phosphorus in orange. Potential hydrogen bonds are depicted as black dashed lines;;
selected water molecules as blue spheres.
(PDF)
S7 Fig. Multiple sequence alignment of selected ALDHs. from T. brucei and H. sapiens
(HsALDH3A1, P30838;; HsALDH3A2, P51648;; HsALDH3B1, P43353;; HsALDH3B2,
P48448). Secondary structure elements are indicated for TbALDH3A2 (colored by domain:
blue, catalytic domain; red, NAD-binding domain; green, oligomerisation domain) and
HsALDH3A2 (colored in grey, from pdb 4QGK). The predicted C-terminal transmembrane
segment in HsALDH3A2 is indicated and the prenylation/palmitoylation sites in HsALDH3B1
(Cys463 and Cys465) are highlighted in yellow. Note that the respective region in
TbALDH3A2 does not to exhibit predicted transmembrane propensities and is lacking cyste-
ine residues for lipidation.
(PDF)
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S8 Fig. Position of the gatekeeper helix. Structural superposition in cartoon representation of
TbALDH3 (red) with HsALDH3A2 (grey) focussing on the gatekeeper helix and the con-
served hydrogen bonding interaction (dashed line) between K481 and the backbone carbonyl
of F474.
(PDF)
S9 Fig. MS spectrums of AN3057, AN2861 and AN3057-derived metabolites from
FBS-TbALDH3. (A) MS spectrums of the ion precursors from either AN3057 or the metabo-
lite from AN3057+TbALDH3. The [M+H]+ ion at m/z 239.0 was identified with both, indicat-
ing no change in structure. (B) MS spectrums of the ions precursors from either AN2861 or
the metabolites from AN3057+FBS+TbALDH3. The [M-H]- ion at m/z 269.0 was identified
with both AN2861 and F-A1 metabolite, indicating an identical structure, which is consistent
with detecting the [M+H]+ ion at m/z 271.0 from F-A1. The [M-H]- ion at m/z 259.0 was iden-
tified with F-A2 metabolite, resulted from the loss of boron, consistent with detecting the
[M-H2O]+ ion at m/z 243.0 from F-A2. (C) MS spectrums of the ions precursors from the
metabolites derived from AN3057+FBS. The [M+H]+ ion at m/z 255.0 was identified with F1
metabolite, suggesting a conversion from methylamine-aldehyde occurred. The [M+H]+ ion
at m/z 245.0 was identified from F2, indicating the loss of boron, consistent with detecting the
[M-H]- ion at m/z 243.0.
(PDF)
S10 Fig. Synthesis of (4-(1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-5-yloxy)phenyl)
methanaminium chloride (AN3057). To the solution of 4-(1-hydroxy-1,3-dihydrobenzo[c]
[1,2]oxaborol-5-yloxy)benzonitrile (1.2 g, 4.78 mmol) in EtOH (150 mL) under N2 was added
Pd/C (10 wt.%, 0.178 g). The reaction mixture was hydrogenated for 26.5 h using a H2 balloon
at room temperature with stirring. The mixture was filtered, rotary evaporated and purified by
silica gel column eluted with MeOH containing 0.6%volume NH4OH (3 mL 28–30% NH4OH
to 500 mL MeOH). The white solid obtained was dissolved in water (80 mL) and 6N HCl (2
mL) was added, filtered and the filtrate was lyophilized to give the desired salt (4-(1-hydroxy-
1,3-dihydrobenzo[c][1,2]oxaborol-5-yloxy)phenyl)methanaminium chloride as white solid
(0.93 g, 3.19 mmol, yield 66.7%). M.p. > 250˚C. 1H-NMR (DMSO-d6, 300 MHz): δ 9.18 (s,
1H), 8.43 (br. s, 3H), 7.74 (d, J = 8.1 Hz, 2H), 7.52 (d, J = 8.7 Hz, 2H), 7.08 (d, J = 8.7 Hz, 1H),
6.98–6.94 (m, 2H), 4.91 (s, 2H) and 3.99 (br. q, J = 4.8 Hz, 2H) ppm. Purity (HPLC): 94.9% at
254 nm. MS: m/z = 256 (M+1, ESI+) and m/z = 255 (M-, ESI-).
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